Fabrizio Schipani

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib

Greta Bagnolini, Domenico Milano, Marcella Manerba et al. · Journal of Medicinal Chemistry · 2020 · 53 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16

Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells

Marinella Roberti, Fabrizio Schipani, Greta Bagnolini et al. · European Journal of Medicinal Chemistry · 2019 · 52 citations · Full text

Medicine, Cancer Biology, Oncology +16

Identification of RAD51–BRCA2 Inhibitors Using <i>N</i>-Acylhydrazone-Based Dynamic Combinatorial Chemistry

Greta Bagnolini, Beatrice Balboni, Fabrizio Schipani et al. · ACS Medicinal Chemistry Letters · 2022 · 24 citations · Full text

Pharmacy, Molecular Biology, Oncology +14

The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination

Fabrizio Schipani, Marcella Manerba, Roberto Marotta et al. · International Journal of Molecular Sciences · 2022 · 20 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +15

An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer

Samuel H. Myers, Laura Poppi, Francesco Rinaldi et al. · European Journal of Medicinal Chemistry · 2023 · 20 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15